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Summary
Objectives: Validate use of a commercially available immunoassay for measurement of bone alkaline phosphatase (BAP) in equine serum
and synovial ﬂuid (SF), and investigate the effects of osteochondral (OC) injury in horses on BAP concentrations in serum and SF.
Methods: SF was collected from 37 joints of 34 Thoroughbred (TB) racehorses undergoing arthroscopic surgery for the removal of OC frag-
ments from either the carpal joints (n¼ 18) or the metacarpo-/metatarsophalangeal (MP) joints (n¼ 19). SF was also obtained from 52 joints of
16 normal TB horses, collected bilaterally from carpal joints of 10 horses (n¼ 40), and MP joints of six horses (n¼ 12). Blood was obtained
from all 50 horses. A commercially available immunoassay was validated and subsequently used to determine equine serum and SF BAP
concentrations. Correlations to radiographic and arthroscopic scores were assessed.
Results: BAP concentrations were signiﬁcantly lower in serum from horses with OC injury in their carpal or MP joints than in serum from nor-
mal horses. SF BAP concentrations in normal and OC injured carpal joints were signiﬁcantly higher than MP joints. BAP concentrations were
signiﬁcantly higher in SF from OC injured carpal joints than normal. BAP concentrations were affected by joint sampled, with age having a sig-
niﬁcant interaction. Concentrations of BAP in the serum (<30 U/L), SF (>22 U/L) and a ratio of SF to serum 0.5 were predictive of OC injury.
Radiographic and arthroscopic scores signiﬁcantly correlated with serum BAP concentrations, and SF:serum BAP correlated with arthroscopic
scores.
Conclusions: Determination of serum and SF BAP concentrations may be beneﬁcial in the investigation of early joint injury. Joint and injury
dependent differences in BAP concentrations allowed the estimation of predictive value for identifying OC injury.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoblasts synthesize and secrete a variety of non-
collagenous proteins, of which, bone alkaline phosphatase
(BAP) is the most abundant1. BAP is a bone speciﬁc iso-
enzyme of the alkaline phosphatases that is coded by the
same gene product as the hepatic, placental, intestinal,
and renal isoenzymes, but differs from these as a result
of post-translational modiﬁcations2. Analysis of total alkaline
phosphatase activity has demonstrated the liver- and bone-
speciﬁc isoenzymes as the most abundant forms (>90%)
identiﬁed in human serum3. The exact role of BAP is still
unknown, but it may contribute to calciﬁcation of bone
matrix4,5 because it is a membrane-bound glycoprotein
that is anchored to the matrix vesicle6,7. It is released into
the circulation after phospholipase cleavage from the mem-
brane in physiopathologic conditions8.*Address correspondence and reprint requests to: Dr Troy
N. Trumble, College of Veterinary Medicine, University of Minnesota,
1365 Gortner Avenue, 225 VMC, St. Paul, MN 55108, USA. Tel:
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779Even though thehealth of subchondral bonemaybe critical
in the development of osteoarthritis (OA)9, few studies have
measured bone-speciﬁc biomarkers to examine bone turn-
over associatedwithOA. In humanOApatients, thepresence
and location of total alkaline phosphatase and/or bone-
speciﬁc isoenzyme in the joint have been described
in situ10e12. The activity levels in human and canine OA
haveprimarily beendetermined in serum,withminimal exam-
ination of SF13. However, the examination of BAP concentra-
tions in both dogs and horses has demonstrated correlation
of SF concentrations with pathologic change14e16.
Biomarkers have been examined in horses to identify
injury-and/or exercise-induced metabolic changes that
occur in both bone and joints14,17e21. Most examine the re-
sponse of bone turnover in relationship to skeletal develop-
ment and/or exercise, independently of the joint, or the
resultant metabolic changes of the extracellular cartilage
matrix and synovium in response to joint injury and/or exer-
cise, independently of the bone. As a result of high-speed
exercise, horses will commonly sustain injury to subchon-
dral bone. This may result in an osteochondral (OC) frag-
ment, exposing subchondral bone to the synovial cavity.
The resultant debris, inﬂammation, and instability can even-
tually progress to OA; most horses with OC injury have
780 T. N. Trumble et al.: Equine BAP validationevidence of OA. Therefore, OC injury in the horse is a useful
model to examine the relationship of concurrent injury to
bone and cartilage and the resulting development of OA.
The aims of the present study were to: (1) validate use of
a commercially available immunoassay for the measure-
ment of BAP in equine serum and SF, (2) investigate the ef-
fects of OC injury on serum and SF BAP concentrations in
horses, (3) establish BAP as a biomarker for non-invasive
investigation of OA by comparing BAP concentrations to
radiographic and arthroscopic scores, and (4) evaluate
the inﬂuences of age, gender, and joint injured on the
BAP concentrations in equine serum and SF.Materials and methodsSTUDY ANIMALS AND SAMPLESSerum and SF were aseptically collected from 37 joints of 34 Thorough-
bred (TB) racehorses (1e7 years of age; median age 3 years) undergoing
arthroscopic surgery for the removal of exercise-induced OC fragments.
These fragments were removed from the dorsoproximal, medial or lateral as-
pect of the ﬁrst phalanx in 14 metacarpophalangeal (MCP) joints and ﬁve
metatarsophalangeal (MTP) joints, as well as from the dorsal articular bor-
ders of the third, radiocarpal, or intermediate carpal bones in 13 middle car-
pal (MC) joints and the dorsal articular borders of the distal radius, proximal
intermediate or radiocarpal bones in ﬁve antebrachiocarpal (ABC) joints. Six-
teen horses were females, 12 were intact males, and six were castrated
males. Serum and SF were also aseptically collected from 16 normal TB
horses (2e6 years of age; median age 4 years) to use as controls. Control
horses were determined to be free of orthopedic disease based on their clin-
ical, lameness, and radiographic examinations. Ten horses were castrated
males and six were females. SF was collected bilaterally from the MC and
ABC joints of 10 horses (n¼ 40), and bilaterally from the MCP joints of six
horses (n¼ 12).
Blood was collected from the jugular vein via needle venipuncture. After
being allowed to clot, serum samples were centrifuged and decanted. SF
was collected by aseptic needle arthrocentesis. If SF samples were contam-
inated with blood, they were also centrifuged and decanted. All clinical and
control samples were stored at 80C until assayed. Sample collection
was approved by the University of Florida Institutional Animal Care and
Use Committee.RADIOGRAPHIC AND ARTHROSCOPIC SCORESAll joints used in the study were radiographed prior to SF sampling. A nu-
merical scoring system was developed for radiographic scoring of the carpal
and MCP joints. There were 10 categories of radiographic changes that were
each graded by two blinded surgeons (TNT and MPB) from 0 to 3 to make up
a total radiographic score of 0e30. Joint space narrowing, soft tissue swell-
ing/effusion, subchondral bone sclerosis, and subchondral bone lucency
were all graded as: 0¼ none, 1¼mild, 2¼moderate, 3¼ severe. The num-
ber of osteophytes and enthesophytes that were present in each joint was
determined and graded as: 0¼ none, 1¼ 1e2 present, 2¼ 3e4 present,
or 3¼>4 present. The size of the largest osteophyte or enthesophyte was
determined and subjectively graded as: 0¼ none, 1¼ small, 2¼medium,
or 3¼ large. OC fragments were graded according to the number of frag-
ments present: 0¼ none, 1¼ 1 fragment, 2¼ 2 fragments, 3¼>2 frag-
ments. The size of the largest OC fragment was determined and
subjectively graded as: 0¼ none, 1¼ small, 2¼medium, or 3¼ large.
Medical records, including surgery reports, arthroscopic photographs and
videos, were examined for all 34 horses undergoing arthroscopic surgery for
the removal of fragments. A modiﬁed arthroscopic scoring system was devel-
oped that could be used in any joint and would speciﬁcally account for injury
associated with OC fragmentation. A total of 11 categories were graded by
two blinded surgeons (TNT and MPB) and summed to make up a total arthro-
scopic score of 0e37. The total numeric score takes into account ﬁve cate-
gories of inﬂammation (graded 0e3)22,23, two categories associated with the
fragments (graded 0e3), and, four categories of degenerative cartilage
changes related to the fragments (graded 0e4)23e25. Inﬂammation was
graded as: 0¼ none, 1¼mild, 2¼moderate, 3¼ severe for the following
categories: hyperemia, petechiation, increase in synovial villi density/thicken-
ing, presence of new villi/rice body formation, and villi atrophy/ﬂattening with
ﬁbrin and adhesion formation. The OC fragment was graded from 0 to 3 as
described above in the radiographic grading and was based on the number
and size of the largest fragment. The degree of cartilage damage was graded
based on the worst lesion present. The relationship of cartilage damage to
the OC fragment was graded as: 0¼ normal, 1¼ localized to fragment,
2¼ kissing (opposing articular surface) lesion present, 3¼ extends onto
cartilage surface of the affected bone, with or without a kissing lesion, or4¼ extensive, including large parts of the articular surface. Extension of car-
tilage damage from the fragment was graded as: 0¼ localized to fragment,
1¼minimal ﬁbrillation or fragmentation at the edge of defect left by fragment,
extending no more than 5 mm from fracture line, 2¼ cartilage degeneration
extending more than 5 mm from the defect, including up to 30% of articular
surface of bone, 3¼ loss of 50% or more of articular cartilage from affected
bone, or 4¼ signiﬁcant loss of subchondral bone24. Depth of cartilage dam-
age surrounding the fragment was graded as: 0¼ normal, 1¼ swelling/
softening, 2¼ superﬁcial ﬁbrillation, 3¼ deep ﬁbrillation down to bone,
4¼ exposure of subchondral bone. Depth of cartilage damage of the kissing
lesion was also graded as: 0¼ normal, 1¼ swelling/softening, 2¼ superﬁcial
ﬁbrillation, 3¼ deep ﬁbrillation down to bone, 4¼ exposure of subchondral
bone.PROCEDURE FOR THE BAP IMMUNOASSAYConcentrations of BAP were measured in equine serum and SF using
a commercially available immunoassay (Metra BAP, Quidel Corporation,
San Diego, CA). This immunoassay uses a puriﬁed murine monoclonal anti-
BAP antibody that has high afﬁnity for the bone-speciﬁc isoform and low
cross-reactivity with the liver isoform of alkaline phosphatase (3e8%)26.
Serum and SF samples were analyzed without digestion or dilution.VALIDATION OF THE BAP IMMUNOASSAY FOR EQUINE USEThe assay was validated for use in equine serum and SF by determining
the precision, speciﬁcity, sensitivity, accuracy, linearity of dilution, and stabil-
ity for each ﬂuid. From six of the normal horses, fresh serum was aseptically
collected from the jugular vein and SF was aseptically collected from 12 MC
and 12 ABC joints. Each ﬂuid was pooled together for further processing and
analysis. Internal quality control (QC) samples were prepared utilizing the
highest concentration standard provided by the manufacturer (140 U/L).
Pooled samples were spiked with high (QCH), medium (QCM) and low
(QCL) levels of BAP. For each ﬂuid, the prepared QCH, QCM, and QCL sam-
ples were pooled together for further analyses.
The reproducibility of the standard curve was evaluated by computing the
mean optical density (OD) and the percent coefﬁcient of variation (CV) at
each standard point as well as with the included low and high controls
from the manufacturer. The intra-assay CV was determined using three of
the same QCH, QCM, and QCL analyzed in duplicate on the same plate.
The inter-assay CV was determined using the same QCH, QCM, and QCL
samples analyzed in duplicate across three different plates. To demonstrate
parallelism, dilutions of 1:2, 1:4, 1:8, and 1:10 were compared with the stan-
dard curve that was derived using the standards provided by the manufac-
turer by comparing the absorbance to the concentration. Detection limit of
the assay was analyzed using the assay buffer. The lowest limit of detection
was deﬁned as two standard deviations above the mean of the assay buffer.
Each of the QC samples (high, medium, and low) was assayed along with
the original pooled sample (background) and the percent recovery for each
was determined to identify whether BAP measurement agreed with the
actual amount present in the sample. Percent recovery was calculated as:
100 (amount of BAP recovered from QCH, QCM, or QCL)/(amount of
BAP added to the pooled sampleþ background BAP amount in the pooled
sample). The linearity of the BAP assay was analyzed by serially diluting
the samples at 1:2, 1:4, 1:8, and 1:10 to determine whether the results
were directly proportional to the concentration of BAP in the sample. The
concentration of each dilution was determined from the standard curve,
and the observed concentration was plotted against the reciprocal of the
dilution (1/dilution). Stability of the BAP analyte was analyzed across two
plates by comparing fresh QCH, QCM, and QCL samples analyzed immedi-
ately after sample collection as well as after 24 h at room temperature, after
24 h at 4C, and then after one to four freeze/thaw cycles at 80C.STATISTICAL ANALYSISStatistical evaluation was performed by the use of personal computer-
based statistical software (SPSS 15.0 for Windows, SPSS, Inc., Chicago, IL).
Normal distribution of the data was determined by producing normality plots.
A one-way ANOVA was performed on serum and SF BAP concentrations
using Tukey’s pairwise test for multiple comparisons. A KruskaleWallis anal-
ysis was performed on the SF:serum BAP and radiographic scores using
Dunn’s test for multiple comparisons. A ManneWhitney unpaired t test
was performed on the arthroscopic scores. A multivariate general linear
model was used to determine what factors contribute to the serum and SF
BAP concentrations. The model included serum and SF BAP concentrations
from horses undergoing arthroscopic surgery as dependent variables. Age
(grouped into three ranges: 2, >2 to 5, and >5 years of age), gender
(intact male, female, and castrated male), location (left fore, right fore, left
hind, and right hind limbs), and joint sampled (MCP, MTP, MC, and ABC)
were analyzed as ﬁxed effects and total radiographic and arthroscopic
scores were analyzed as covariates. The main effects and interactions of
781Osteoarthritis and Cartilage Vol. 16, No. 7the ﬁxed effects on the model were determined using Hotelling’s Trace.
Spearman’s rank correlation was used to determine direct correlations.
Contingency tables were analyzed using Fisher’s exact test to determine the
sensitivity, speciﬁcity, predictive values and an odds ratio. P< 0.05 was
considered signiﬁcant.
ResultsBAP ASSAY VALIDATIONThe OD values of the standards exhibited acceptable
inter-assay precision over 10 plates with an overall mean
CV of 8.1% (range 4.8e12.3%). The inter-assay precision
of the low control (mean CV of 7.4%) was better than the
high control (mean CV of 10.8%). No intra-assay CV was
determined for the standards. Samples exhibited accept-
able inter-assay precision over three plates with an overall
mean CV of 7.2% (range 5.7e9.6%) for the serum and
7.1% (range 4.8e8.8%) for SF. Samples exhibited accept-
able intra-assay precision over three plates with an overall
mean CV of 3.3% (range 0.1e8.1%) for the serum and
2.6% (range 0.2e7.5%) for SF. Figure 1(A) demonstrates
parallelism of equine serum and SF sample dilutions
when compared to the standard curve. The lowest detection
limit of the assay was determined to be 1.42 U/L. The per-
cent recoveries ranged from 103.1 to 116.1% for the serum
with the most accurate recoveries recorded at the high con-
centrations, whereas percent recoveries for SF ranged from
64.8 to 91.2% with highest recoveries recorded at the low
concentrations (Table I). Figure 1(B) demonstrates linearity
of equine serum and SF sample dilutions. Serum and SF
stability results demonstrated that overnight sample pro-
cessing was better if performed at 4C rather than at
room temperature (Table II). For the serum QCM and
QCL samples, there was an increase in BAP after three
freeze/thaw cycles, whereas the QCH sample had minimal
loss of BAP out to three freeze/thaw cycles. For the SF and
QCM samples, there was minimal loss of BAP out to two
freeze/thaw cycles, whereas there was minimal loss for
the QCH and QCL samples out to four freeze/thaw cycles.BAP CONCENTRATIONS IN EQUINE SF AND SERUMFig. 1. Validation of BAP immunoassay for use in equine serum and
SF. (A) Demonstration of parallelism: absorbance vs concentration
of diluted (1:2, 1:4, 1:8, and 1:10) pooled serum and SF samples
(squares) is compared with the curve derived from standards pro-
vided by the manufacturer (triangles). Coefﬁcient correlations for
the samples (black) and standards (gray) are listed next to each
corresponding line. (B) Demonstration of linearity: dilutions of
serum (solid lines) and SF (dashed lines) samples at 1:2, 1:4,
1:8, and 1:10 for each QCH, QCM, and QCL samples. The concen-
tration of each dilution was determined from the standard curve,
and the observed concentration was plotted against the reciprocal
of the dilution (1/dilution).Signiﬁcantly lower BAP concentrations (P< 0.01) were
measured in serum of horses with OC injury of carpal and
MP joints than in serum of normal horses [Fig. 2(A)]. How-
ever, serum BAP concentrations were not signiﬁcantly dif-
ferent when compared between horses with carpal and
MP OC injury. When comparing the serum concentrations
between normal horses and OC injured horses, 91% of
the horses that had serum BAP concentrations< 30 U/L
had MP or carpal OC injury (Table III).
SF BAP concentrations in the carpal joints of normal
horses were 2.2 times higher than SF BAP concentrations
in the MP joints of normal horses [P< 0.05; Fig. 2(B)]. SF
BAP concentrations from OC injured carpal joints were
2.7 times higher than concentrations from OC injured MP
joints (P< 0.001). In addition, SF BAP concentrations
from the OC injured carpal joints were signiﬁcantly higher
than from normal carpal joints (P< 0.001). When compar-
ing SF concentrations between normal carpal joints and
OC injured carpal joints, 80% of the horses that had syno-
vial BAP concentration> 22 U/L had carpal OC injury
(Table III). However, there was no signiﬁcant difference be-
tween SF BAP concentrations in normal and OC injured MP
joints. When combining the OC injured carpal and MP sam-
ples, SF BAP concentrations were positively correlated to
the joint that was affected (Table IV).Multivariate analysis of all factors demonstrated that se-
rum and SF BAP concentrations varied between the joints
that were sampled (R¼ 0.717; P¼ 0.008). There was a sig-
niﬁcant interaction of the joint sampled with age (R¼ 0.828;
Table I
Percent recovery from spiked samples (measured concentration/expected concentration 100) for serum and SF BAP concentrations
Serum SF
Expected concentration
(U/L)
Measured concentration
(U/L)
% Recovery Expected concentration
(U/L)
Measured concentration
(U/L)
% Recovery
63.965 65.921 103.057 46.784 30.295 64.755
53.965 60.242 111.632 32.784 28.211 86.053
41.965 48.702 116.054 18.884 17.223 91.208
782 T. N. Trumble et al.: Equine BAP validationP¼ 0.005). This interaction resulted from horses 2 years
of age having higher serum BAP concentrations associated
with MP joints than older horses. When the interaction was
removed from the analysis, joint sampled (carpal or MP)
was the only factor that had a signiﬁcant effect on the serum
and SF BAP concentrations (R¼ 0.315; P¼ 0.02).
Serum BAP concentrations were signiﬁcantly higher
(P< 0.001) than SF BAP concentrations from either joint
from normal horses. In addition, horses with OC injured
MP joints had serum BAP concentrations that were signiﬁ-
cantly higher than their concurrent SF concentrations
(P< 0.001). However, serum and SF BAP concentrations
from horses with OC injured carpal joints were not signiﬁ-
cantly different. SF:serum BAP was the same between nor-
mal horses and horses with OC injured MP joints [Fig. 2(C)],
but was signiﬁcantly increased in horses with OC injured
carpal joints (P< 0.001). Horses with OC injury in the car-
pus had 180 times greater likelihood of having an SF:serum
BAP 0.5 compared to normal horses (Table III). In addi-
tion, SF:serum BAP correlated with arthroscopic score for
both joints (R¼ 0.494; P¼ 0.006; Table IV). When ana-
lyzed by joint, SF:serum BAP from horses with OC injured
MP joints showed correlation with arthroscopic scores
(R¼ 0.610; P¼ 0.007).
Total MP and carpal radiographic scores could be used to
identify differences between normal and OC injured joints
(Table III). Total radiographic score for OC injured MP joints
(meanSD; 7.8 4.6) was 5.5 times higher (P< 0.001)
than normal MP joints (1.4 1.4). Total radiographic score
for OC injured carpal joints (8.5 4.0) was 3.9 times higher
(P< 0.001) than normal carpal joints (2.2 1.4). However,
there was no signiﬁcant difference in radiographic scores
between OC injured MP and carpal joints. As an approxi-
mate indicator of the severity of lesions, radiographic
scores 10 (out of a maximum score of 30) were identiﬁed
in 7/18 (38.9%) of the OC injured MP joints and 9/20 (45%)
of OC injured carpal joints. In addition, there was no signif-
icant difference in arthroscopic scores between OC injured
MP (12.4 4.6) and carpal (15.3 6.9) joints. Similarly,Table I
Stability data for the QCH, QCM, and QCL samples for serum and SF d
processed immediately (Fsh), after 24 h at room temperature (Rm T
(F/T 1e4). Percent difference (% Diff) represents difference in concentr
or F/T sam
Fsh Rm Tmp % Diff 4(C % Diff F/T 1
Serum
QCH 59.7 63.4 6.3 58.8 1.6 54.1
QCM 49.2 58.8 19.6 49.4 0.5 45.5
QCL 39.6 48.0 21.3 40.6 2.6 37.3
SF
QCH 40.5 45.4 12.2 41.5 2.6 41.8
QCM 32.7 32.1 1.8 31.3 4.2 29.8
QCL 16.6 20.0 20.6 19.1 14.7 18.5arthroscopic scores 20 (out of a maximum score of 37)
were identiﬁed in 1/18 (5.6%) of the OC injured MP joints
and 4/16 (25%) of OC injured carpal joints. There was a pos-
itive correlation (R¼ 0.645; P¼ 0.0001) between radio-
graphic and arthroscopic scores for OC injured MP and
carpal joints. For OC injured joints, both radiographic and
arthroscopic scores increased with age, however, both
decreased as the serum BAP concentrations increased
(Table IV).
Discussion
The aims of this study were to validate the use of a com-
mercially available immunoassay for the measurement of
BAP in equine serum and SF and to investigate the effects
of OC injury on serum and SF BAP concentrations in
horses. Other assays for BAP activity in horses have
been reported27,28. The enzyme immunoassay used in the
present study has essentially no cross-reactivity with the
liver isoform (3e8%)26. Our results indicated that this assay
has cross-reactivity with equine serum and SF by demon-
strating precision, speciﬁcity, sensitivity, accuracy, linearity,
and stability.
Intra- and inter-assay variations are indicators of assay
precision, with CV< 10e15% usually considered as ac-
ceptable. Our intra-assay CV was <9% and the inter-assay
variation was <10% for both the serum and SF. SF was
not digested with hyaluronidase prior to analysis. This
apparently did not affect pipetting accuracy, based on pre-
cision of the assay. In addition, the elimination of hyaluron-
idase digestion allowed the analysis of fresh samples and
prevented any potential breakdown of BAP. Spiking recov-
eries ranged from 103.1 to 116.1% for serum and 64.8 to
91.2% for SF. Although percent recovery was less for
SF, highest recoveries were recorded at low concentra-
tions, where most of the biological activity was present in
the samples (Table I). BAP activity in serum was more
labile than in SF (Table II). In fact, serum BAP activity ac-
tually increased when the samples were incubated at roomI
emonstrating BAP concentrations (U/L) after samples were either
mp), after 24 h at 4(C, or after one to four freeze/thaw cycles
ations between the fresh samples vs the room temperature, 4(C,
ples
% Diff F/T 2 % Diff F/T 3 % Diff F/T 4 % Diff
9.4 47.4 20.6 48.2 19.2 62.9 5.4
7.6 53.9 9.5 59.2 20.4 54.1 10.0
5.8 38.8 2.0 41.7 5.5 42.1 6.5
3.3 44.8 10.8 35.1 13.3 36.1 11.0
8.6 28.6 12.3 24.8 24.1 25.1 23.1
11.3 15.2 8.6 15.0 9.4 15.3 8.1
Fig. 2. Scattergram with mean BAP concentrations in (A) serum,
(B) SF, and (C) the ratio of SF to serum for normal horses and horses
withOC injury of the carpal (triangles) orMP (circles) joints. Signiﬁcant
differencesbetweengroupsare representedas *P< 0.05, **P< 0.01,
and ***P< 0.001. Red lines represent concentrations (<30 U/L for
serum,>22 U/L for carpalSF, and0.5 for carpalSF:serum) forwhich
there is predictive value in determining OC injury from normal.
Table III
Sensitivity, specificity, positive predictive value, negative predictive
value and odds ratio to discriminate between OC injured and
normal horses when serum BAP concentration is <30 U/L, carpal
SF BAP concentration is >22 U/L, carpal SF:serum ratio0.5, or
radiographic score4 for the MP joints, or 5 for the carpus
Sensitivity
(%)
Speciﬁcity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Odds
ratio
Serum BAP
<30 U/L
60 88 91 50 10.5
Carpal SF
BAP >22 U/L
60 92 80 82 18.0
Carpal SF:
serum BAP
0.5
94 92 83 97 180.0
MP joint
radiographic
score 4
83 92 94 79 55.0
Carpal joint
radiographic
score 5
80 93 84 90 49.3
783Osteoarthritis and Cartilage Vol. 16, No. 7temperature, 4C, and after three freeze/thaw cycles for
the QCM and QCL samples. The reason for this phenom-
enon is not known, but it has been previously reported re-
garding stability of human alkaline phosphatase activity in
serum29,30.
Most studies of biomarkers in humans are limited by the
availability of ﬂuids. Urine and serum are the most com-
monly analyzed ﬂuids because of ease of collection. SF is
rarely analyzed because it is difﬁcult to obtain adequate vol-
umes and consent for collection. However, SF should be
the best ﬂuid for characterization of events occurring in
a speciﬁc joint. Therefore, differential analysis of both se-
rum and SF from the same patient is extremely valuable31.
The horse is a good species to use for this type of analysis.
Horses are a good translational model of OA in humans32,
and SF can be regularly obtained in high volumes (usually
>2 mL) without lavage.
To the authors’ knowledge, the current study is the ﬁrst to
demonstrate signiﬁcantly lower serum BAP concentrations
from horses with OC injury compared to normal horses.
We also demonstrated a concurrent signiﬁcant increase in
SF BAP concentrations from OC injured horses compared
to normal horses. In addition, we found a joint-dependent
difference in SF BAP concentration. Carpal joints had signif-
icantly higher SF BAP concentrations than MP joints in both
normal horses and those with OC injury [Fig. 2(B)]. In vivo
and in vitro equine studies have reported differences in
SF biomarker concentrations between joints from normal
horses33e36. Most of these studies have demonstrated
that the synovial structures distal to the MP joints normally
had higher biomarker concentrations compared to more
proximal joints33e35, as well as greater response to cyto-
kines33. Findings may be similar when analyzing SF from
different joints in humans because differences have been
demonstrated in knee and ankle cartilages in response to
cytokines and cytokine antagonists37. These discrepancies
between joints may be due to intrinsic differences, such as
joint size, biomechanical properties of the cartilage and
bone, amount of force transferred across the joint, as
well as biochemical composition and gene expression of
articular cartilage in response to anabolic and catabolic fac-
tors33e37. Therefore, differences in biomarker concentra-
tions between different joints are important to consider
regardless of the biomarker studied.
Table IV
Correlations for variables studied in OC injured horses. Significant correlations are represented by an asterisk. Age, gender, and joint affected
are represented as categorical variables. Age groups: 1¼2 years, 2¼>2 to 5 years, and 3¼>5 years. Gender: 1¼ intact male,
2¼ female, and 3¼ castrated male. Joint affected: 1¼MCP, 2¼MTP, 3¼MCJ, and 4¼RCJ
Age Gender Joint
affected
SF BAP
concentration
Serum BAP
concentration
SF:serum Radiographic
score
Arthroscopic
score
Age 1.00 R¼ 0.308 R¼ 0.005 R¼ 0.131 *R[L0.428 R¼ 0.287 *R[ 0.467 *R[ 0.492
P¼ 0.057 P¼ 0.976 P¼ 0.428 P[ 0.01 P¼ 0.095 P[ 0.003 P[ 0.003
Gender 1.00 R¼ 0.177 R¼ 0.039 R¼0.232 R¼ 0.032 R¼ 0.176 R¼ 0.227
P¼ 0.281 P¼ 0.815 P¼ 0.179 P¼ 0.854 P¼ 0.920 P¼ 0.197
Joint affected 1.00 *R[ 0.554 R¼ 0.032 R¼ 0.316 R¼ 0.046 R¼ 0.038
P[ 0.0001 P¼ 0.856 P¼ 0.065 P¼ 0.782 P¼ 0.830
SF BAP concentration 1.00 R¼0.130 *R[ 0.845 R¼ 0.241 R¼ 0.290
P¼ 0.458 P[ 0.0001 P¼ 0.145 P¼ 0.096
Serum BAP concentration 1.00 *R[L0.592 *R[L0.414 *R[L0.451
P[ 0.0001 P[ 0.015 P[ 0.012
SF:serum 1.00 R¼ 0.293 *R[ 0.494
P¼ 0.093 P[ 0.006
Radiographic score 1.00 *R[ 0.645
P[ 0.0001
Arthroscopic score 1.00
Signiﬁcant correlations are represented as bolded R and P values.
784 T. N. Trumble et al.: Equine BAP validationIn general, serum concentrations of bone biomarkers de-
pend upon the number of osteoblasts required for bone for-
mation as well as clearance rate of the biomarker38. Serum
BAP concentrations in the present studywere 26e28% lower
in horses with OC injury when compared to normal horses
[Fig. 2(A)]. Our ﬁndings were similar to other osteoblastic bio-
marker studies in humans where there was a decrease in se-
rum BAP (19%)39 or osteocalcin (15%)40 concentrations in
women with OA compared to normal women. However,
Campion et al. reported high concentrations of osteocalcin
in serum of people with destructive OA41. Therefore, our
results support the hypotheses that lower than normal
concentrations of osteoblastic biomarkers in the serum are
indicative of non-destructive OA39e41. The cause for this
decrease is unknown, but may be related to lower bone
turnover39,40.
Decrease in serum BAP concentrations in early OA may
be associated with the structure of BAP when it is released
into serum. Most BAP in serum is in the soluble dimer
form42,43. However, in OA there may be greater release of
the hydrophobic domain of the BAP enzyme that anchors
it to the plasma membrane of the osteoblast. If this an-
chor-bound form is released into serum, it can form aggre-
gates with other proteins and lipids42,43. These complex
formations may prevent the immunoassay from recognizing
BAP.
Our ﬁndings that serum concentrations decreased while
SF concentrations increased raise the question whether
BAP in serum may be ﬁltrated into the SF. Previous reports
have suggested that a basic way to examine the relation-
ship between serum and SF is to calculate a ratio of SF:
serum44,45. The assumption was that a ratio of SF:serum>1
would be suggestive of local production of the bone bio-
marker in the joint45, whereas ratios<1 would indicate
that BAP in the joint was due to diffusion from the blood44.
Using this approach in the present study would suggest that
most of the SF BAP concentration was derived from the
blood [Fig. 2(C)], because SF:serum BAP was <1 for all
normal horses and the majority of horses with OC injury.
Normal horses in our study generally had lower ratios
than horses with OC injury. This suggests that there wasnot an increase in the amount of ﬁltration of BAP from the
blood to the joint when OC injury was present. On the con-
trary, it suggests that with OC injury, there was greater local
production of BAP in the joint. This was most obvious in
horses with carpal OC injury where many ratios were
0.5. In fact, a ratio of 0.5 for the horses with OC injury
in their carpal joints was predictive of OC injury. Using
this ratio assumes passive diffusion of BAP across the sy-
novial membrane. None of these studies have investigated
the kinetic movement of the biomarker of interest across the
synovial membrane and therefore have not conﬁrmed that
the site of origin was either blood or SF. Nonetheless, the
concept of a ratio between SF and serum BAP concentra-
tions is useful.
Fuller et al. reported increased SF BAP concentrations in
TB racehorses with OC injury compared to contralateral
joints. Although these investigators concluded that the
increased concentration supported the view that bone is
involved in the early process of OA, they offered no expla-
nation for the source of the BAP in SF14. Alkaline phospha-
tase activity has been shown to be present around the cell
surfaces of hypertrophic chondrocytes in growth plates as
well as matrix vesicles, allowing it to participate in mineral-
ization and subsequent calciﬁcation46. Therefore, the most
likely source for increased SF BAP concentrations after
OC fragmentation is the subchondral bone. Studies of os-
teochondritis dissecans have demonstrated that BAP can
be immunolocalized just below the tidemark and can be re-
leased toward the surface of the joint when a ﬁssure is pres-
ent in the articular cartilage47. The results of the present
study may support the subchondral bone as a major source
of locally produced BAP in OC injured joints, considering
that the extent of subchondral bone injury and exposure is
usually greater in carpal joints than in MP joints.
Another likely reason for injury-related increase in SF
BAP concentrations is the formation of osteophytes and en-
thesophytes. Osteophytes have been shown to go through
the same morphogenetic process as growth plate cartilage
by the development of hypertrophic chondrocytes48. It has
been demonstrated that osteophytes have high alkaline
phosphatase activity49. In a previous canine cranial cruciate
785Osteoarthritis and Cartilage Vol. 16, No. 7transection model of OA, a positive correlation (R¼ 0.6705;
P< 0.0001) was identiﬁed between the SF BAP concentra-
tion and the radiographic osteophyte score16. A direct corre-
lation to osteophyte production could not be made in the
present study, but most OC injured horses had some de-
gree of osteophytosis, making osteophytes a likely contrib-
utory source of SF BAP. Immunohistochemical studies in
rheumatoid arthritis have suggested that BAP could be pro-
duced in the synovium, however, there was little support for
this in OA patients12.
To the authors’ knowledge, there are no veterinary radio-
graphic or arthroscopic scoring systems for OC fragmenta-
tion that can be applied to different joints. As a modiﬁcation
of previously described scoring systems, we devised radio-
graphic and arthroscopic scoring systems for OC injury that
could be used in both the carpal and MP joints of horses.
The radiographic scoring system accounted for the pres-
ence of soft tissue swelling, number of OC fragments, os-
teophytes, enthesophytes, and subchondral bone changes
such as lysis and sclerosis16,50. The arthoscopic scoring
accounted for the presence of OC fragments, inﬂammation,
and extent of cartilage damage22e25.
These scoring systems appeared to cover the spectrum
of injury that was visible either radiographically or arthro-
scopically and were a good indicator of the degree of path-
ologic change present. In support of this, radiographic
scores were good predictors of the severity of joint damage
associated with OC injury compared to normal carpal and
MP joints, in which no OC injury was present (Table III).
This same comparison could not be made with the arthro-
scopic scoring system because the control horses were
not examined arthroscopically. For OC injured joints, the
highest severity scores tended to occur more often in the
carpus than the MP joints for both scoring systems. In addi-
tion, we identiﬁed a signiﬁcant positive correlation between
the radiographic score and the arthroscopic score (R¼
0.645; P¼ 0.0001), indicating that the two scoring systems
could identify increasing pathologic change. Serum BAP
concentrations negatively correlated with both radiographic
and arthroscopic scores indicating that as serum BAP de-
creased, the radiographic and arthroscopic scores in-
creased (Table IV). Interestingly, SF BAP concentrations
did not correlate with either the radiographic or arthroscopic
scoring systems. However, SF:serum BAP showed a posi-
tive correlation with arthroscopic score (Table IV). SF:serum
BAP was the only indicator for MP joints that BAP concen-
trations correlated with the degree of pathologic change
present in the joint (R¼ 0.610; P¼ 0.007).
Potential sources of variability for bone biomarkers in
horses include age27,51, gender52,53, circadian rhythms54,
and seasonal effects55. We attempted to minimize sources
of variability, but had some limitations. All horses were of
the same breed and groups were age-matched as closely
as possible. Similar to previous studies27,51, age was a fac-
tor in the present study, with younger horses (2 years)
having higher serum BAP concentrations than horses> 2
years of age. However, we saw no effect of age on SF
BAP concentrations. Age also correlated with radiographic
and arthroscopic scores, with scores tending to increase
with age (Table IV). Gender did not correlate with BAP con-
centrations or radiographic or arthroscopic scores. The ef-
fects of circadian rhythm and seasonal differences were
minimized in the normal horses by sampling all horses in
the morning as well as in the spring. However, the time
and season of sampling could not be controlled for the
OC injured horses because samples were collected at the
time of arthroscopic surgery. However, based on previousreports54,56, it is anticipated that the effects of these sources
of variation would not heavily contribute to the results.
This study had some additional limitations. With regards
to the validation, no standard stock solution could be ob-
tained from the manufacturer, so internal QC samples
were prepared using the highest concentration standard
provided by the manufacturer (140 U/L). Because of this,
only the lower half of the standard curve was analyzed ex-
tensively. Although it would be ideal to examine the entire
curve by dividing it into thirds, examination of the lower
half of the curve was acceptable because that is where
values for our equine serum and SF samples were de-
tected. When used with human serum, this assay shows
only 3e8% cross-reactivity with the liver isoenzyme. How-
ever, it has been suggested that horse serum may have
slight differences in the carbohydrate component of the liver
isoenzyme compared to humans27. We did not examine the
cross-reactivity of the assay with other isoenzymes and
therefore the amount of cross-reactivity with the liver isoen-
zyme in horses is unknown.
Some factors are difﬁcult to control when collecting clini-
cal samples from horses with OC injury. This includes exer-
cise and medication history. Racehorses may be trained
and treated in many different ways that could affect concen-
trations of BAP. Controlled, longitudinal studies of experi-
mentally created OC injury would allow control of these
factors.
This study validated the use of a commercially available
immunoassay for the measurement of BAP in equine serum
and SF. The assay was used to identify joint and injury de-
pendent differences in the SF concentration of BAP when
comparing normal and OC injured carpal and MP joints.
In addition, serum and SF concentrations, as well as the
ratio of the two, demonstrated a strong predictive value of
BAP concentration for identifying OC injury. Based on the
results of this study, determination of serum and SF BAP
concentrations may be beneﬁcial in the investigation of
early joint injury.Conﬂict of interest
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